Famotidine Augmentation in Schizophrenia: Hope or Hype?
J Clin Psychiatry 2013;74(9):e855-e858
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Famotidine is a potent, selective, histamine H2 receptor antagonist used in the treatment of peptic ulcer disease. Famotidine (40–200 mg/d) augmentation of antipsychotic medication in treatment-resistant schizophrenia has been the subject of intermittent study for more than 2 decades. Case reports, open studies, and small randomized controlled trials (RCTs) have documented various improvements in total ratings of psychosis, negative symptoms, general psychopathology, and other measures; adverse effects have been few or none. Despite the modestly encouraging results of a recent, widely publicized RCT, for theoretical reasons as well as for reasons related to the quality of the available literature, it is premature to seriously consider famotidine as a possible antipsychotic augmentation agent. It is particularly noteworthy that, given that the drug was initially studied for possible efficacy against deficit or negative symptoms of schizophrenia, no RCT has established such an efficacy.